Phase 1, Randomized Open Label, Multiple Dose, Parallel Study To Assess The Immunogenicity Of Multiple Subcutaneous (sc) Doses Of The Proposed Pegfilgrastim Biosimilar (Pf-06881894) And Us-approved Neulasta (Registered) In Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 14 Nov 2017
At a glance
- Drugs Pegfilgrastim (Primary)
- Indications Febrile neutropenia; Neutropenia
- Focus Pharmacodynamics
- Sponsors Pfizer
- 07 Nov 2017 Status changed from not yet recruiting to recruiting.
- 27 Sep 2017 Planned End Date changed from 26 Apr 2018 to 9 Jun 2018.
- 27 Sep 2017 Planned primary completion date changed from 26 Apr 2018 to 9 Jun 2018.